Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
mTOR inhibitor |
| gptkbp:ATCCode |
L01EG04
|
| gptkbp:CASNumber |
572924-54-0
|
| gptkbp:chemicalFormula |
C53H84N4O14
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
gptkb:ARIAD_Pharmaceuticals |
| https://www.w3.org/2000/01/rdf-schema#label |
ridaforolimus
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
inhibits mTOR pathway
|
| gptkbp:molecularWeight |
989.24 g/mol
|
| gptkbp:relatedTo |
gptkb:everolimus
gptkb:sirolimus gptkb:temsirolimus |
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:synonym |
AP23573
Deforolimus |
| gptkbp:target |
gptkb:mTOR
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:rapalogs
gptkb:sirolimus gptkb:mechanistic_target_of_rapamycin_pathway |
| gptkbp:bfsLayer |
6
|